Fractyl Health appoints Michael Wartell as independent director
GUTS•Fractyl Health appointed Michael Wartell as an independent Class III director effective November 2, 2026. The appointment expands the board from nine to ten members, and Wartell’s term expires at the 2027 annual meeting.
1. Board appointment
Wartell is president of Bluerose Associates LLC and has experience as an independent director guiding public and private companies through complex situations.
